ADMA as reported
ADMA Biologics, Inc. reported $510M of revenue over the trailing twelve months, +11% on the year before. 11 reported series are charted on this page, each one as filed.
$510M
Revenue, trailing twelve months · to Q1 2026 · +11% against the twelve months before
- Net Income
- $165M
Net Income · −20% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $108M
Free Cash Flow · +19% year on year · trailing twelve months to Q1 2026
- Op Margin
- 42%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $510M | +11% | Q1 2026 |
| Net Income | $165M | −20% | Q1 2026 |
| EPS | $0.68 | −20% | Q1 2026 |
| Gross Margin | 61% | n/a | Q1 2026 |
| Op Margin | 42% | n/a | Q1 2026 |
| Net Margin | 33% | n/a | Q1 2026 |
| ROE | 44% | n/a | Q1 2026 |
| ROA | 31% | n/a | Q1 2026 |
| ROIC | −62% | n/a | Q1 2020 · 24 quarters behind |
| Free Cash Flow | $108M | +19% | Q1 2026 |
| P/E | 14.2 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
ADMA Biologics, Inc. (ADMA) - Revenue & ProfitRevenue & ProfitADMA Biologics, Inc. (ADMA)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com